NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 873.1 DKK | -2.74% |
|
-2.04% | +25.07% |
| May. 02 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
| May. 02 | Novo Nordisk, Eli Lilly's Weight-Loss Drugs Get Price Cuts in UK | MT |
| Sales 2024 * | 287B 41.31B | Sales 2025 * | 347B 49.87B | Capitalization | 3,879B 558B |
|---|---|---|---|---|---|
| Net income 2024 * | 103B 14.85B | Net income 2025 * | 125B 18.02B | EV / Sales 2024 * | 13.7 x |
| Net Debt 2024 * | 53.94B 7.76B | Net Debt 2025 * | 12.36B 1.78B | EV / Sales 2025 * | 11.2 x |
| P/E ratio 2024 * |
37.9
x | P/E ratio 2025 * |
31
x | Employees | 63,845 |
| Yield 2024 * |
1.4% | Yield 2025 * |
1.62% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
| 1 day | -2.74% | ||
| 1 week | -2.04% | ||
| Current month | -0.93% | ||
| 1 month | +0.69% | ||
| 3 months | +16.69% | ||
| 6 months | +28.83% | ||
| Current year | +25.07% |
1 week
853.30
916.90
1 month
845.10916.90
Current year
688.80932.00
1 year
504.40932.00
3 years
227.03932.00
5 years
155.08932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 192 M€ | +12.28% | ||
| 10.45% | 5 M€ | +8.01% | ||
| 5.40% | 18 M€ | +3.01% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 873.1 | -2.74% | 4,750,846 |
| 24-05-01 | 897.7 | -0.54% | 1,825,419 |
| 24-04-30 | 902.6 | +2.01% | 4,324,631 |
| 24-04-29 | 884.8 | -0.20% | 1,796,260 |
| 24-04-26 | 886.6 | +2.28% | 2,082,169 |
Delayed Quote Nasdaq Copenhagen, May 02, 2024 at 10:59 am EDT
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
08:15am
- Q1 2024 Earnings Call - London
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
897.7
DKK
Average target price
904.2
DKK
Spread / Average Target
+0.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.07% | 571B | |
| +29.68% | 699B | |
| -4.35% | 364B | |
| +17.65% | 326B | |
| +3.77% | 286B | |
| +14.68% | 236B | |
| +4.71% | 198B | |
| -12.43% | 194B | |
| -3.79% | 154B | |
| -3.34% | 149B |
- Stock Market
- Equities
- NOVO B Stock
